Hinge Health, Inc.
HNGE
$87.70
+0.70%
Hinge Health, Inc. operates a digital health platform that uses AI-powered motion tracking to treat and prevent chronic musculoskeletal (MSK) pain, serving employers and health plans. As a pioneer in the digital MSK therapy market, the company differentiates itself through its proprietary patient movement data and clinically validated outcomes, positioning it as a leader in a rapidly growing niche. The current investor narrative centers on the company's accelerating revenue growth, recent transition to profitability, and the potential for its AI-driven platform to capture a large share of the MSK treatment market, as highlighted by recent analyst upgrades and positive news flow.…
HNGE
Hinge Health, Inc.
$87.70
Related headlines
HNGE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $89.27 and implied upside of +1.8% versus the current price.
Average Target
$89.27
0 analysts
Implied Upside
+1.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $125
Analyst target range
Hinge Health is covered by 15 analysts, with a consensus recommendation of 'Buy' (mean recommendation 1.56 on a 1-5 scale, where 1 is Strong Buy). The average target price is $89.27, implying a modest 2.5% upside from the current price of $87.09. The distribution leans bullish, with recent ratings from Morgan Stanley, Keybanc, Barclays, and Wells Fargo all at Overweight, and Canaccord Genuity and Raymond James at Buy/Outperform. Only Baird rates it Neutral. The consensus is clearly positive, but the limited upside to the average target suggests the stock is already pricing in much of the good news. The target price range spans from a low of $65.00 to a high of $125.00, indicating significant uncertainty. The high target of $125 assumes continued strong growth and multiple expansion, potentially driven by further market share gains or new product launches. The low target of $65 implies risks such as competitive pressure, slower growth, or margin compression. The wide spread (92% range from low to high) reflects high uncertainty, typical for a high-growth company in a nascent market. Recent analyst actions have been uniformly positive, with no downgrades in the past month, reinforcing the bullish sentiment. However, the narrow upside to the average target suggests that near-term gains may be limited unless the company delivers upside surprises.
Bulls vs Bears: HNGE Investment Factors
Hinge Health presents a compelling growth story with accelerating revenue (47% YoY), a recent profitability inflection (19.3% net margin), and strong free cash flow generation ($206.2M TTM). The balance sheet is pristine with minimal debt. However, the stock's 87% year-to-date rally has pushed it near the 52-week high, and the average analyst target offers only 2.5% upside, suggesting limited near-term appreciation. The bull case is supported by the company's leadership in the digital MSK market and AI-driven moat, while the bear case centers on valuation risk and potential growth deceleration. The single most important tension is whether the company can sustain its 47% revenue growth rate and expand margins further; if growth decelerates below 30%, the current premium valuation (25.6x forward P/E) could compress significantly. Currently, the bull case has stronger evidence given the accelerating fundamentals, but the risk/reward is balanced at current levels.
Bullish
- Revenue Growth Accelerating to 47% YoY: Q1 2026 revenue of $182.3M grew 47.2% year-over-year, accelerating from 39.2% in Q4 2025 and 37.1% in Q3 2025. This consistent acceleration signals strong market adoption and expanding client base.
- Profitability Inflection Achieved: Net income turned positive at $35.1M in Q1 2026, with net margin of 19.3%, a dramatic improvement from a loss of $575.7M in Q2 2025. Gross margin expanded to 84.6% from 70.3% a year earlier, demonstrating operating leverage.
- Strong Free Cash Flow Generation: Free cash flow was $43.0M in Q1 2026, with trailing twelve-month FCF of $206.2M. This cash generation supports organic growth investments and reduces reliance on external financing.
- Minimal Debt on Balance Sheet: Debt-to-equity ratio is only 0.021, indicating virtually no leverage. The current ratio of 1.47 and cash position of $188.1M provide ample liquidity for growth initiatives.
Bearish
- Limited Upside to Average Target: The average analyst target of $89.27 implies only 2.5% upside from the current price of $87.09. This suggests much of the good news is already priced in, limiting near-term return potential.
- High Valuation Premium to Peers: Forward P/E of 25.6x represents a 28% premium to the healthcare information services sector average of ~20x. While justified by growth, any deceleration could trigger multiple compression.
- Stock Near 52-Week High: At $87.09, the stock trades at 95.2% of its 52-week range and has gained 87.3% over the past year. The rapid ascent increases risk of a mean-reversion pullback, especially given implied high volatility.
- Negative ROE from Accumulated Losses: ROE is -139.6% due to historical losses, though improving profitability should turn it positive. The negative ROE highlights the company's past capital inefficiency.
HNGE Technical Analysis
Hinge Health is in a powerful sustained uptrend, with the stock up 87.3% over the past year and currently trading at 95.2% of its 52-week range ($30.08–$91.50). The price sits at $87.09, near the 52-week high of $91.50, indicating strong momentum and bullish sentiment, though it also suggests the stock may be approaching overbought territory. The 1-year relative strength versus SPY is 68.9%, confirming significant outperformance. Short-term momentum is exceptionally strong, with the stock gaining 29.9% in the last month and 101.0% over the past three months. This acceleration aligns with the longer-term uptrend, showing no signs of divergence; the 1-month relative strength of 29.6% versus SPY underscores the stock's recent outperformance. The rapid rise, however, raises the risk of a mean-reversion pullback, especially given the stock's beta is not provided but implied high volatility. Key support lies near the 52-week low of $30.08, while resistance is at the 52-week high of $91.50. A breakout above $91.50 would signal continued upside, potentially targeting the analyst high of $125. Conversely, a breakdown below recent support around $85 could indicate profit-taking. The stock's beta is not available, but its 1-year price change of 87.3% versus SPY's 18.4% suggests significantly higher volatility, warranting careful position sizing.
Beta
—
—
Max Drawdown
-48.5%
Largest decline past year
52-Week Range
$30-$92
Price range past year
Annual Return
+86.8%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +26.3% | -0.6% |
| 3m | +96.8% | +5.4% |
| 6m | +111.2% | +8.3% |
| 1y | +86.8% | +18.3% |
| ytd | +92.5% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Hinge Health's revenue trajectory is accelerating strongly, with Q1 2026 revenue of $182.3 million growing 47.2% year-over-year, up from 39.2% growth in Q4 2025 and 37.1% in Q3 2025. The company has consistently grown revenue from $89.8 million in Q2 2024 to $182.3 million in Q1 2026, demonstrating a clear acceleration trend. This robust growth is driven by increasing adoption of its digital MSK platform, with no segment data available but likely broad-based. The accelerating growth supports the investment case for a high-growth healthcare technology leader. Profitability has turned sharply positive: net income was $35.1 million in Q1 2026, compared to a loss of $575.7 million in Q2 2025 (which included a large stock-based compensation charge). Gross margin expanded to 84.6% in Q1 2026 from 70.3% in Q2 2025, reflecting operating leverage. The company is now profitable on a GAAP basis, with a net margin of 19.3% in Q1 2026, a dramatic improvement from negative margins in prior quarters. The balance sheet is strong: debt-to-equity is only 0.021, indicating minimal leverage, and the current ratio is 1.47, suggesting adequate liquidity. Free cash flow was $43.0 million in Q1 2026, and trailing twelve-month free cash flow reached $206.2 million, demonstrating strong cash generation. ROE is negative at -139.6% due to accumulated losses, but improving profitability should turn ROE positive over time. The company's cash position of $188.1 million provides a solid cushion for growth investments.
Quarterly Revenue
$182307000.0B
2026-03
Revenue YoY Growth
+47.2%
YoY Comparison
Gross Margin
84.6%
Latest Quarter
Free Cash Flow
$206166000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Since net income is positive ($35.1 million in Q1 2026), the P/E ratio is the primary valuation metric. The trailing P/E is negative (-8.7) due to prior losses, but the forward P/E is 25.6, reflecting expected earnings growth. The gap between trailing and forward P/E implies the market anticipates a significant earnings recovery, which is consistent with the recent profitability inflection. The P/S ratio of 6.3 provides an alternative perspective for a high-growth company. Compared to the industry, Hinge Health trades at a premium: its forward P/E of 25.6x is above the healthcare information services sector average (typically around 20x), representing a 28% premium. This premium is justified by the company's superior revenue growth (47% YoY) and expanding profitability, as well as its leadership in the digital MSK niche. Historically, Hinge Health's P/S ratio has ranged from 16.6x (Q1 2026) to 41.9x (Q2 2023), and the current 6.3x is near the low end of its historical P/S band. However, the P/E history is less meaningful due to past losses. The current valuation reflects the market's optimism about sustained growth and margin expansion, but it is not extreme relative to the company's own history or growth rate.
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation dependency on sustained high growth. With a forward P/E of 25.6x (28% premium to sector), any deceleration in revenue growth below 30% could trigger multiple compression and a sharp stock decline. Although the company now generates positive net income ($35.1M in Q1 2026), it has a history of large losses, including a $575.7M loss in Q2 2025 due to stock-based compensation. The negative ROE of -139.6% indicates past capital inefficiency, though this is improving. Revenue concentration risk exists as the company operates primarily in the digital MSK niche, making it vulnerable to changes in employer healthcare spending or competitive dynamics.
Market & Competitive Risks: The stock's 87.3% one-year gain versus SPY's 18.4% implies significantly higher volatility, making it susceptible to sector rotation out of growth stocks. The digital MSK market is attracting competitors, including Teladoc and Omada Health, which could pressure margins. Regulatory risk includes potential changes to healthcare reimbursement policies or data privacy laws that could impact the platform's adoption. The stock's beta is not provided, but its price action suggests high correlation with growth stock sentiment, which could shift if interest rates remain elevated.
Worst-Case Scenario: In a severe downturn, the stock could retest its 52-week low of $30.08, representing a 65.5% decline from the current price of $87.09. This scenario could be triggered by a growth deceleration below 20%, margin compression from competitive pricing, or a broad market selloff in growth stocks. The analyst low target of $65.00 implies a 25.4% downside, while the 52-week low implies a more extreme 65.5% loss. Given the stock's recent parabolic rise, a 30-50% correction is plausible if fundamentals disappoint.